Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corp (NQ: ADPT )

4.635 +0.265 (+6.06%)
Streaming Delayed Price Updated: 1:33 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adaptive Biotechnologies Corp

Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platform 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQ 
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
From Adaptive Biotechnologies
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.